This document summarizes a study examining the effect of statin therapy on the progression of coronary artery calcification. The study found that patients treated with cerivastatin had a significantly lower median increase (8.8%) in coronary calcium scores compared to untreated patients (25% increase). Patients whose LDL cholesterol was reduced to under 100 mg/dl by treatment had an average decrease in calcium scores (-3.4%). The results suggest that statin therapy can slow the progression of calcification and underlying atherosclerosis. However, limitations include the open-label and prematurely ended nature of the study.
Impact of statins and beta-blocker therapy on mortality after coronary artery...Paul Schoenhagen
Abstract
Background: We conducted a retrospective cohort study of patients after first-time isolated coronary artery bypass graft surgery (CABG) and assessed the impact of a discharge regimen including beta-blockers and statin therapy and their relationship to long-term all cause mortality and major adverse cardiovascular events (MACE).
Methods: We identified patients age >18 years, undergoing first time isolated CABG from 1993 to 2005. Patients were identified using the Cardiovascular Information Registry (CVIR). We collected follow-up information at 30, 60, 90 days and yearly follow-up. The registry is approved for use in research by the institutional review broad.
Results: We identified 5,205 patients who underwent single isolated CABG between January 1993 and December 2005. The mean age was 64.5±9.7 years and over 70% were male. There was a significant difference in the low density lipoproteins (LDL) concentration between those with or without statin medications (134±41.9 mg/dL) (no statin) vs. 126±44.8 mg/dL (with statin), P=0.001. A discharge regimen with statin therapy was associated with and overall reduction in 30 day, 1 year and long-term mortality. In addition, overall the triple ischemic endpoint of death, myocardial infarction (MI) and stroke was also significantly lower in the statin vs. no-statin group. In addition, statin and beta-blockers exerted synergistic effect on overall mortality outcomes short-term and in the long-term. We note that the predictors of overall death include no therapy with statin therapy and age [hazard ratios (HR) 1.1, 95% CI: 1.04-1.078, P<0.001] and presence of renal failure (HR 2.0, P=0.005). The estimated 11-year Kaplan Meier curves for mortality between the two groups starts to diverge immediately post discharge after single isolated CABG and continue to diverge through out the follow-up period.
Conclusions: A post-discharge regimen of statins independently reduces overall and 1 year mortality. These results confirm those of earlier studies within a contemporary surgical population and support the current clinical guidelines.
In cardiology practice, we often come across patients presenting with anginal pain who undergo coronary angiogram which reveals either normal or non-obstructive epicardial coronaries. Importance is given to epicardial coronaries and the coronary microvasculature which could be the cause of angina is often overlooked. These patients are then labeled to have non-cardiac chest pain and musculoskeletal or psychogenic etiology is suggested. However, with growing interest in coronary microvasculature which are the tiny blood vessels at the tissue level in myocardium, diagnostic modalities and treatment options for coronary microvascular disease are being explored.
Impact of statins and beta-blocker therapy on mortality after coronary artery...Paul Schoenhagen
Abstract
Background: We conducted a retrospective cohort study of patients after first-time isolated coronary artery bypass graft surgery (CABG) and assessed the impact of a discharge regimen including beta-blockers and statin therapy and their relationship to long-term all cause mortality and major adverse cardiovascular events (MACE).
Methods: We identified patients age >18 years, undergoing first time isolated CABG from 1993 to 2005. Patients were identified using the Cardiovascular Information Registry (CVIR). We collected follow-up information at 30, 60, 90 days and yearly follow-up. The registry is approved for use in research by the institutional review broad.
Results: We identified 5,205 patients who underwent single isolated CABG between January 1993 and December 2005. The mean age was 64.5±9.7 years and over 70% were male. There was a significant difference in the low density lipoproteins (LDL) concentration between those with or without statin medications (134±41.9 mg/dL) (no statin) vs. 126±44.8 mg/dL (with statin), P=0.001. A discharge regimen with statin therapy was associated with and overall reduction in 30 day, 1 year and long-term mortality. In addition, overall the triple ischemic endpoint of death, myocardial infarction (MI) and stroke was also significantly lower in the statin vs. no-statin group. In addition, statin and beta-blockers exerted synergistic effect on overall mortality outcomes short-term and in the long-term. We note that the predictors of overall death include no therapy with statin therapy and age [hazard ratios (HR) 1.1, 95% CI: 1.04-1.078, P<0.001] and presence of renal failure (HR 2.0, P=0.005). The estimated 11-year Kaplan Meier curves for mortality between the two groups starts to diverge immediately post discharge after single isolated CABG and continue to diverge through out the follow-up period.
Conclusions: A post-discharge regimen of statins independently reduces overall and 1 year mortality. These results confirm those of earlier studies within a contemporary surgical population and support the current clinical guidelines.
In cardiology practice, we often come across patients presenting with anginal pain who undergo coronary angiogram which reveals either normal or non-obstructive epicardial coronaries. Importance is given to epicardial coronaries and the coronary microvasculature which could be the cause of angina is often overlooked. These patients are then labeled to have non-cardiac chest pain and musculoskeletal or psychogenic etiology is suggested. However, with growing interest in coronary microvasculature which are the tiny blood vessels at the tissue level in myocardium, diagnostic modalities and treatment options for coronary microvascular disease are being explored.
This presentation discusses the latest evidence for blood transfusion triggers in the intensive care unit of various clinical condition including severe sepsis, GI bleed, post surgical cases, and post cardiac surgery among other cnditions
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Esv2n36
1. Editorial Slides
VP Watch – September 11, 2002 - Volume 2, Issue 36
Influence of Statin Therapy on Progression ofInfluence of Statin Therapy on Progression of
Coronary CalcificationCoronary Calcification
Matthew J. Budoff, MD, FACCMatthew J. Budoff, MD, FACC
Assistant Professor of MedicineAssistant Professor of Medicine
Division of CardiologyDivision of Cardiology
Harbor- UCLA Medical Center
Torrance, CA, USA
2. Coronary Calcification
Coronary Calcification has been demonstrated
to be a marker of atherosclerosis and
cardiovascular risk1
Electron Beam Tomography (EBT) is a non-
invasive method to detect and quantify
coronary calcification
Prognostic studies have demonstrated an
increased risk of future cardiac events with
increased coronary calcium scores1
3. Progression of AtherosclerosisProgression of Atherosclerosis
Regression studies have predominantly been
performed with angiographic trials, requiring
multiple invasive angiographic studies
These studies are typically 2-4 years in
duration, demonstrating small but significant
changes, with luminal diameter changing by
microns
It is well known that Luminal stenosis by
angiography poorly quantitates atherosclerotic
burden
4. EBT and ProgressionEBT and Progression
Several studies with EBT have demonstrated
progression of calcium scores of up to 50% per
year2,3,4
Variability of sequential EBT scans has been
demonstrated to range from 8-24% (mean), with
median values of 5-8%5,6
It has been demonstrated that EBT can track
progression of coronary calcium over time, and
progression of CAC has been demonstrated to be
associated with increased cardiovascular risk7,8
5. Progression of CAC and The
Relation to Therapy
(adapted from ref 7)
AUTHOR n KNOWN CAD? No Therapy Statin
Treatment
Type of Therapy
Janowitz 20 No
Yes
18%
27%
-------- ---------
Callister 27 No 44% -------- ---------
Callister 149 No 52%
(n = 44)
5%
(n = 105)
Statins
Maher 81 No 24% -------- ---------
Budoff 299 No 36%
(n = 239)
15%
(n = 60)
Statins
Mitchell 347 No 21% --------- ----------
Brown 160 Yes 40% 20% Simvastatin, Niacin
Achenbach 66 No 25% 8.8% Cerivastatin 0.3
mg/day
6. Annual Event Rate with Progression
of CAC
(Adapted from Reference 8)
0
1.5
6.45
0
1
2
3
4
5
6
7
AnnualEventRates
No progression 1-20% Increase >20% Increase
Annual CAC Score Change Shah et al, AHA 2001
7. Calcium Score progression with
increasing LDL Cholesterol
(Adapted from Reference 2)
+120%
0
–80%
60 120 200
LDL (mg/dL)
Treated Untreated Suboptimal Therapy (LDL >120 mg/dl)
Callister et al. N Engl J Med. 1998;339:1972-1978.
CACScoreChange
8. Achenbach et al, Circulation
2002
66 patients with known high cholesterol
underwent EBT scanning
Baseline calcium scores were 155 mm3
Patients were observed for a mean of 14
months
Follow-up scan revealed score increase to
201 mm3
(25%)
9. Treatment Arm - Cholesterol
Patients were then treated (open label) on
Cerivastatin 0.3 mg/dl for 12 months
Mean LDL was reduced from was 164 mg/dl
to 107 mg/dl (35% reduction, p<0.0001)
Mean HDL increased from 51 mg/dl to 52
mg/dl (1.7% increased, not significant)
Mean Triglycerides decreased from 184 mg/dl
to 152 mg/dl (17%, p=0.004)
10. EBT Changes with Statin Therapy
EBT score increased from 201 mm3
to 203
mm3
Median increase in score (on treatment was
8.8%, significantly lower than no therapy
25%, p<0.0001)
In 32 patients, on-treatment LDL cholesterol
was <100 mg/dl, median change was –3.4%
12. Study Limitations
Study was stopped prematurely due to
Cerivastatin’s withdrawal from the
marketplace
Open Label study
80% triggering of EBT used (higher variability
than early diastolic trigger)
13. Conclusions:
Cerivastatin significantly reduced rates of
coronary calcium progression
Achieving an LDL cholesterol of <100 mg/dl
was associated with a median decrease of
the coronary calcium burden (-3.4%)
This study correlates with retrospective
studies previously published on EBT that
statin therapy will slow calcification deposition
14. Questions:
Does slowing of the calcification burden correlate
with slowing of the atherosclerotic plaque volume ?
Will helical (fast) CT be able to measure these
changes, given the lower reproducibility due to
slower scan times?10
Will slowing of the coronary calcium burden be
associated with a reduction in cardiovascular
events?
15. References
1. Budoff MJ. Prognostic Value of Coronary Artery Calcification. J Clin Out Manag 2001:8;42-48.
2. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo NJ. Effect of HMG-CoA Reductase Inhibitors on Coronary Artery Disease as
Assessed by Electron-Beam Computed Tomography. N Engl J Med 1998;339:1972-8.
3. Maher JE, Bielak LF, Raz JA, Sheedy PF, Schwartz RS, Peyser PA. Progression of coronary artery calcification: A pilot study. Mayo
Clin Proc 1999;74:347-355.
4. Budoff MJ, Lane KL, Bakhsheshi H, et al. Rates of progression of coronary calcification by electron beam computed tomography.
Am J Cardiol 2000; 86:8-11.
5. Achenbach S, Ropers D, Mohlenkamp S, et al. Variability of Repeated Coronary Artery Calcium Measurements by Electron Beam
Tomography. Am J Cardiol 2001;87:210-213.
6. Mao SS, Bakhsheshi H, Lu B, Liu SCK, Oudiz RJ, Budoff MJ. Effect of ECG triggering on reproducibility of coronary artery calcium
scoring. Radiology 2001;220(3):707-11.
7. Budoff MJ and Raggi P: Coronary artery disease progression assessed by electron-beam computed tomography. Am J Cardiol
2001;88(suppl):46E-50E.
8. Shah AS, Sorochinsky B, Mao SS, Naik TK, Budoff MJ. Cardiac events and progression of coronary calcium score using electron
beam tomography. Circulation 2000;102;II-604.
9. Achenbach S, Ropers D, Pohle K, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a
prospective evaluation. Circulation. 2002;106(9):1077-82.
10. Qanadli SD, Mesurolle B, Aegerter P, et al. Volumetric quantification of coronary artery calcifications using dual-slice spiral CT
scanner: improved reproducibility of measurements with 180 degrees linear interpolation algorithm. J Comput Assist Tomogr
2001;25(2):278-286.
Editor's Notes
&lt;number&gt;
&lt;number&gt;
Using the volumetric calcium scoring method, it is possible to explore the potential for regression of atherosclerotic plaque volume with primary or secondary CHD prevention.
In a retrospective study, Callister et al tested the hypothesis that treatment with HMG-CoA reductase inhibitors (statins) would result in a change in coronary plaque volume as measured by EBT. One hundred and forty-nine patients with no history of CHD who had been referred for EBT screening were evaluated. All patients underwent a baseline EBT scan and then returned for a follow-up scan 1 year later. After their initial screening, 70% of the patients had received lipid-lowering treatment with a statin and 30% had not. Patients were classified into 3 groups; Group 1 – no statin therapy; Group 2 – statin therapy and follow-up average LDL-C levels &gt;120 mg/dL; Group 3 – statin therapy and follow-up average LDL-C &lt;120 mg/dL.
Callister TQ, Raggi P, Cooil B, et al. N Engl J Med. 1998;339:1972-1978.